Eurobio Scientific Team
Bilanci
Eurobio Scientific è quotata all'Euronext Growth Paris (ALERS) dal 2005.
2024
(in francese)
2023
(in francese)
2022
(in francese)
2021
(in francese)
Comunicati stampa
Comunicati stampa
- FY 2025 revenue
- Replacement of a Statutory Auditor
- Results for the first semester of fiscal year 2025
- Eurobio Scientific completes the acquisition of Life Science unit of Voden Medical Instruments Spa in Italy
- Resultat Annuel 2024 – Growth of core business and strategic execution
- Eurobio Scientific rafforza la sua presenza in Italia
- Termination of the liquidity contract
- Calendar of financial publications 2025
- Eurobio Scientific: successful takeover bid at the end of its first period, reopening of the offer from 4 to 17 December
- Opening of the public purchase offer until November 27
- Eurobio Scientific: lifting of the last regulatory suspensive condition to the takeover bid project initiated by EB Development
- Results for the first half of 2024
- Eurobio Scientific completes acquisition of Endopredict® genomic test from Myriad Genetics
- Suspension of the liquidity contract
- First half 2024, a solid start of the financial year in an uncertain environment – PROPOSED TENDER OFFER
- Agreement to acquire the ENDOPREDICT gene expression test for breast cancer
- Publication of the 2023 financial annual report
- 2023 annual results, growth in Core Business and strategic deployment
- 2023 Annuel revenue at 130,1 MEUR
- Capital reduction through cancellation of treasury shares-2024
- Catherine Courboillet to join the Board as an Independant Member
- Availability of the 2023 half-yearly financial report
- GenDx reduces organ matching time to 3 hours
- H1 2023 Results: Solid performance of Core Business and acceleration of strategic deployment
- Acceleration of strategic deployment in the first half of 2023
- Riduzione del capitale mediante annullamento di azioni proprie
- All resolutions approved at the 2023 Annual General Meeting – The Board of Directors appoints a new governance
- Acquisition of D.I.D. in Italy
- First IVDR CE marking of PCR tests
- Publication of the 2022 annual financial report
- 2022 annual results : very strong performance and strengthening of the Core Business
- Wietse Mulder, CEO of GenDx, holds a 2% stake in Eurobio Scientific
- Eurobio Scientific formalises the appointment of Anne-Sophie Herelle as Group CFO
- 2022 annual turnover of €152.5M
- H2 2022 report on the liquidity contract
- Exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
- Half-year financial report available
- H1 2022 Results: continued growth of non-COVID activity
- Eurobio Scientific finalizes the acquisition of GenDx, international HLA diagnostics specialist
- Eurobio Scientific signs an agreement to acquire GenDx, international HLA diagnostics specialist
- First half turnover of €83.6 million maintained at a high level
- Half-year report on liquidity contract
- Launch of 2 new proprietary tests : new variants of SARS-CoV-2, and Monkeypox
- Eurobio Scientific’s annual shareholders’ meeting
- Eurobio Scientific expands into Benelux by acquiring the diagnostic company Biomedical Diagnostics NV
- Closing of the Strategic Partnership with NEXTSTAGE AM
- Availability of the 2021 annual financial report
- Eurobio Scientific partners with Dr. Nino Guy Cassuto for the development of a new PCR test for male fertility
- CE mark for Eurobio Scientific’s new proprietary test for the detection of Omicron BA.x, BA.2 and Delta variants of SARS-CoV-2
- Maintaining high level results in 2021
- New priority test for the detection of Omicron BA.x, BA.2 and Delta of SARS-CoV-2
- Strategic partnership with NextStage AM
- 2021 TURNOVER : Exceptional level of €184.1million
- Eurobio Scientific launches the exclusive distribution of the first saliva self-test for HIV testing in France
- Eurobio Scientific confirms its eligibility to the pea-pme system
